Mealey's (October 14, 2022, 11:09 AM EDT) -- SAN DIEGO — A federal judge in California granted final distribution of a $12.75 million settlement fund in a securities class action against a pharmaceutical company and certain of its senior executives on claims that they misrepresented adverse clinical trial results for the company’s metastatic breast cancer (MBC) treatment candidate in violation of federal securities laws....